UNSPSC 51273022: Piperocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2RH0XR1MB, chemically known as 1-piperidinepropanol, 2-methyl-, benzoate (ester), hydrochloride but more generally known as piperocaine hydrochloride, which bears US NIH Compound Identifier 10781. Most nations, for tariff and trade purposes, schedule piperocaine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PIPEROCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Piperocaine hydrochloride bears US NLM identifiers UMLS ID C0770379 and NCI Concept Code C90655. SMILES: CC1CCCCN1CCCOC(=O)C2CCCCC2.CL.

UNSPSC 51273022 Piperocaine hydrochloride is a Commodity code that, based on recent state and local solicitations, covers pharmaceutical products sourced through multiple distribution channels to support public health programs, community health initiatives, and state pharmacy benefit systems. State and local governments procuring under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The actual work involves competitive procurement of pharmaceutical inventory—including naloxone, generic multi-source medications, and over-the-counter products—with requirements for FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, established wholesaler relationships, and quarterly or scheduled deliveries to public health facilities.

Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted recent solicitations under or aligned with this code tier. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with a response deadline of July 26, 2023, and quarterly deliveries to Seminole County Community Health Building in Sanford. The Texas HHS Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. Recent activity spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles serving as a primary procurement mechanism for multi-state pharmaceutical distribution.